Skip to Content
MilliporeSigma
  • Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Brain & development (2010-07-16)
Vincenzo Belcastro, Laura Pierguidi, Nicola Tambasco
ABSTRACT

Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection. Recent observations suggest that levetiracetam is both safe and effective against post-stroke seizures. In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
USP
Levetiracetam, United States Pharmacopeia (USP) Reference Standard
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Supelco
Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material